Angiotensin II infusion in man is proinflammatory but has no short-term effects on thrombin generation in vivo

Thrombosis Research

Volumn 124, Issue 1, 2009, Pages 110-115

  Ekholm, M ^a   Kahan, T ^b   Jorneskog G ^b   Broijersen A ^c   Wallen N H ^b  

^a DANDERYD HOSPITAL   (Sweden)

^b Division of Geriatric Medicine   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin II; atherosclerosis; cytokines; inflammation; interleukin 6; leucocyte count

Indexed keywords

ANGIOTENSIN II; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL HYPERLIPEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; IN VIVO STUDY; INFLAMMATION; INFUSION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REST; THROMBOSIS;

ADULT; ANGIOTENSIN II; ANTITHROMBINS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; INFLAMMATION; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64649104901     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.12.040     Document Type: Article

References (31)

1. Nickenig G. Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens 16 Suppl 3 (2002) S26-S33
2. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., and Coppack S.W. C-reactive protein in wealthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction - A potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol 19 (1999) 972-978
3. Skurk T., van Harmelen V., and Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappa B. Arterioscler Thromb Vasc Biol 24 (2004) 1199-1203
4. Funakoshi Y., Ichiki T., Ito K., and Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension 34 (1999) 118-125
5. Ruiz-Ortega M., Ruperez M., Lorenzo O., Estaban V., Blanco J., Mezzano S., et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kindey. Kidney Int 62 Suppl 82 (2002) S12-S22
6. Krejcy K., Eichler H.G., Jilma B., Kapiotis S., Wolzt M., Zanaschka G., et al. Influence of angiotensin II on circulating adhesion molecules and blood leucocyte count in vivo. Can J Physiol Pharmacol 74 (1996) 9-14
7. Madjid M., Awan I., Willerson J.T., and Ward S. Leucocyte count and coronary heart disease - Implications for risk assessment. J Am Coll Cardiol 44 (2004) 1945-1956
8. Vaughan D.E. Angiotensin and vascular fibrinolytic balance. Am J Hypertens 15 Pt 2 (2002) S3-S8
9. Brown N.J., and Vaughan D.E. Prothrombotic effects of angiotensin. Adv Intern Med 45 (2000) 419-429
10. Nakamura S., Nakamura I., Ma L., Vaughan D.E., and Fogo A.B. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Kidney Int 58 (2000) 251-259
11. Ridker P.M., Gaboury C.L., Conlin P.R., Seely E.W., Williams G.H., and Vaughan D.E. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87 (1993) 1969-1973
12. Lottermoser K., Hertfelder H.J., Gohlke P., Vetter H., and Düsing R. Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects. Clin Exp Hypertens 26 (2004) 13-26
13. Larsson P.T., Schwieler J.H., Wallén N.H., and Hjelmdahl P. Acute effects of angiotensin II on fibrinolysis in healthy volunteers. Blood Coagul Fibrinolysis 10 (1999) 19-24
14. Larsson P.T., Schwieler J.H., and Wallén N.H. Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 11 (2000) 61-69
15. Ekholm M., Wallén N.H., Johnsson H., Eliasson K., and Kahan T. Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. Clin Sci (Lond) 103 (2002) 151-155
16. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., and Motulsky A.G. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 (1973) 1544-1568
17. De Michele M., Iannuzzi A., Salvato A., Pauciullo P., Gentile M., and Iannuzzo G. Impaired endothelium-dependent vascular reactivity in patients with familial combined hyperlipidaemia. Heart 93 (2007) 78-81
18. Simpson H.C., Mann J.I., Meade T.W., Chakrabarti R., Stirling Y., and Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1 (1983) 786-790
19. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., and Sironi L. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 12 (1992) 19-27
20. van Oostrom A.J., van Wijk, and Cabezas M.C. Lipaemia, inflammation and atherosclerosis: Novel opportunities in the understanding and treatment of atherosclerosis. Drugs 64 Suppl 2 (2004) 19-41
21. Duggan J., Nussberger J., Kilfeather S., and O'Malley K. Aging and human hormonal and pressor responsiveness to angiotensin II infusion with simultaneous measurement of exogenous and endogenous Angiotensin II. Am J hypertens 6 (1993) 641-647
22. Wiman B., Andersson T., Hallqvist J., Reuterwall C., Ahlbom A., and de Faire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20 (2000) 2019-2023
23. Carlson K. Lipoprotein fractionation. J Clin Pathol Suppl (Assoc Clin Pathol) 26 (1973) 32-37
24. Jörneskog G., Ekholm M., Kahan T., Bröjersén A., and Wallén N.H. Altered micro- and macrovascular responses to angiotensin II in familial combined hyperlipdemia. J Cardiovasc Med 9 (2008) 1037-1044
25. Luther J.M., Gainer V.G., Murphey L.J., Yu C., Vaughan D.E., and Morrow J.D. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48 (2006) 1050-1057
26. Saad B., Frei K., Scholl F.A., Fontana A., and Maier P. Hepatocyte-derived interleukin-6 and tumor-necrosis factor alpha mediate the lipopolysaccharide-induced acute-phase response and nitric oxide release by cultured rat hepatocytes. Eur J Biochem 229 (1995) 349-355
27. Nagata K., Ishibashi T., Sakamaoto T., Nakazato K., Seino Y., and Yokoyama K. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens 19 (2001) 775-783
28. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
29. Muller J.E., Tofler G.H., and Stone P.H. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79 (1989) 733-743
30. van der Linde N.A., Sijbrands E.J., Boomsma F., and van den Meiracker A.H. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension 47 (2006) 1125-1130
31. Goette A., Bukowska A., Lendeckel U., Erxleben M., Hammwöhner M., Strugala D., et al. Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation 117 (2008) 732-742